AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia

Type(s) of Cancer: Leukemia/Blood/Hematologic
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798